Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Growth hormone therapy in mTBI and PASC
NCT03554265Phase 3Completed
- Sponsor
- The University of Texas Medical Branch at Galveston
- Start
- Aug 2018
- Primary completion
- Oct 2023
- Modality
- Hormone, rProtein (Recombinant Protein), Biologic
- Countries
- 1
01
Overview
Phase 3, open-label trial of somatropin in growth hormone deficiency (GHD), sponsored by The University of Texas Medical Branch at Galveston. Started Aug 2018; status: completed.
02
Drugs
somatropin
03
Conditions
growth hormone deficiency (GHD)
Beyond the preview
Go deeper on NCT03554265.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03554265.